Germany · Delayed Price · Currency is EUR Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of EUR 18.54 million. The enterprise value is 9.87 million.
| Market Cap | 18.54M |
| Enterprise Value | 9.87M |
Important Dates
The next estimated earnings date is Thursday, March 19, 2026.
| Earnings Date | Mar 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 60.89M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.72% |
| Shares Change (QoQ) | +14.45% |
| Owned by Insiders (%) | 5.08% |
| Owned by Institutions (%) | 12.38% |
| Float | 54.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 42.84 |
| PB Ratio | 0.55 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.36 |
| EV / Sales | 22.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.36 |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.81 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -62.12% and return on invested capital (ROIC) is -41.33%.
| Return on Equity (ROE) | -62.12% |
| Return on Assets (ROA) | -37.92% |
| Return on Invested Capital (ROIC) | -41.33% |
| Return on Capital Employed (ROCE) | -86.56% |
| Revenue Per Employee | 3,279 |
| Profits Per Employee | -207,789 |
| Employee Count | 132 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | -980,517 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 5,414 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.10 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of EUR 432,876 and -27.43 million in losses. Loss per share was -0.82.
| Revenue | 432,876 |
| Gross Profit | 147,314 |
| Operating Income | -30.28M |
| Pretax Income | -28.41M |
| Net Income | -27.43M |
| EBITDA | -29.26M |
| EBIT | -30.28M |
| Loss Per Share | -0.82 |
Balance Sheet
The company has 9.75 million in cash and 1.25 million in debt, giving a net cash position of 8.50 million.
| Cash & Cash Equivalents | 9.75M |
| Total Debt | 1.25M |
| Net Cash | 8.50M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 33.95M |
| Book Value Per Share | 0.71 |
| Working Capital | 8.83M |
Cash Flow
In the last 12 months, operating cash flow was -26.57 million and capital expenditures -546,380, giving a free cash flow of -27.11 million.
| Operating Cash Flow | -26.57M |
| Capital Expenditures | -546,380 |
| Free Cash Flow | -27.11M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 34.03% |
| Operating Margin | -6,995.70% |
| Pretax Margin | -6,562.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.72% |
| Shareholder Yield | -11.72% |
| Earnings Yield | -147.91% |
| FCF Yield | -146.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of -1.69 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.69 |
| Piotroski F-Score | 1 |